» Articles » PMID: 24554667

Boosting Functional Avidity of CD8+ T Cells by Vaccinia Virus Vaccination Depends on Intrinsic T-cell MyD88 Expression but Not the Inflammatory Milieu

Overview
Journal J Virol
Date 2014 Feb 21
PMID 24554667
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: T-cell functional avidity is a crucial determinant for efficient pathogen clearance. Although recombinant DNA priming coupled with a vaccinia-vectored vaccine (VACV) boost has been widely used to mount robust CD8+ T-cell responses, how VACV boost shapes the properties of memory CD8+ T cells remains poorly defined. Here, we characterize the memory CD8+ T cells boosted by VACV and demonstrate that the intrinsic expression of MyD88 is critical for their high functional avidity. Independent of selection of clones with high-affinity T-cell receptor (TCR) or of enhanced proximal TCR signaling, the VACV boost significantly increased T-cell functional avidity through a decrease in the activation threshold. VACV-induced inflammatory milieu is not sufficient for this improvement, as simultaneous administration of the DNA vaccine and mock VACV had no effects on the functional avidity of memory CD8+ T cells. Furthermore, reciprocal adoptive transfer models revealed that the intrinsic MyD88 pathway is required for instructing the functional avidity of CD8+ T cells boosted by VACV. Taking these results together, the intrinsic MyD88 pathway is required for the high functional avidity of VACV-boosted CD8+ T cells independent of TCR selection or the VACV infection-induced MyD88-mediated inflammatory milieu.

Importance: Functional avidity is one of the crucial determinants of T-cell functionality. Interestingly, although it has been demonstrated that a DNA prime-VACV boost regimen elicits high levels of T-cell functional avidity, how VACV changes the low avidity of CD8+ T cells primed by DNA into higher ones in vivo is less defined. Here, we proved that the enhancement of CD8+ T cell avidity induced by VACV boost is mediated by the intrinsic MyD88 pathway but not the MyD88-mediated inflammatory milieu, which might provide prompts in vaccine design.

Citing Articles

Myeloid MyD88 restricts CD8 T cell response to radiation therapy in pancreatic cancer.

Medler T, Blair T, Alice A, Dowdell A, Piening B, Crittenden M Sci Rep. 2023; 13(1):8634.

PMID: 37244938 PMC: 10224952. DOI: 10.1038/s41598-023-35834-w.


Improving the expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors.

Chenli Qiu , Wang J, Zhu L, Cheng X, Xia B, Jin Y Front Bioeng Biotechnol. 2022; 10:1027619.

PMID: 36394017 PMC: 9659750. DOI: 10.3389/fbioe.2022.1027619.


Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.

Hu Z, Lu S, Lowrie D, Fan X Front Immunol. 2022; 13:895020.

PMID: 35812383 PMC: 9259874. DOI: 10.3389/fimmu.2022.895020.


Therapeutic Vaccines for the Treatment of HIV.

Chen Z, Julg B Transl Res. 2020; 223:61-75.

PMID: 32438074 PMC: 8188575. DOI: 10.1016/j.trsl.2020.04.008.


Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.

Teck A, Urban S, Quass P, Nelde A, Schuster H, Letsch A Cancer Immunol Immunother. 2020; 69(7):1217-1227.

PMID: 32157447 PMC: 8222032. DOI: 10.1007/s00262-020-02519-6.


References
1.
Larsson M, Fonteneau J, Somersan S, Sanders C, Bickham K, Thomas E . Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol. 2001; 31(12):3432-42. DOI: 10.1002/1521-4141(200112)31:12<3432::aid-immu3432>3.0.co;2-r. View

2.
Richer M, Nolz J, Harty J . Pathogen-specific inflammatory milieux tune the antigen sensitivity of CD8(+) T cells by enhancing T cell receptor signaling. Immunity. 2012; 38(1):140-52. PMC: 3557574. DOI: 10.1016/j.immuni.2012.09.017. View

3.
Reddy J, Bettelli E, Nicholson L, Waldner H, Jang M, Wucherpfennig K . Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramers. J Immunol. 2003; 170(2):870-7. DOI: 10.4049/jimmunol.170.2.870. View

4.
Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W . Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 2012; 189(2):598-605. DOI: 10.4049/jimmunol.1102165. View

5.
Alexander-Miller M . High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res. 2004; 31(1):13-24. DOI: 10.1385/IR:31:1:13. View